G. Viberti

G. Viberti, G. Viberti, A. Raptis, 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Glomerular hyperfiltration as a risk factor for diabetic nephropathy: Five-year report of a prospective study

G. Viberti, 2004, Diabetologia.

Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control.

S. Thomas, G. Viberti, A. Alaveras, 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Diabetes: Excess mortality in well-controlled T1DM without renal disease

G. Viberti, J. Karalliedde, 2015, Nature Reviews Nephrology.

Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease.

L. Gnudi, G. Gruden, G. Viberti, 2000, Journal of the American Society of Nephrology : JASN.

Serum lipids and the progression of nephropathy in type 1 diabetes.

Merlin C. Thomas, M. Taskinen, C. Forsblom, 2006, Diabetes care.

Early functional and morphologic vascular renal consequences of the diabetic state

G. Viberti, 1980, Diabetologia.

Correction of Exercise-induced Microalbuminuria in Insulin-dependent Diabetics After 3 Weeks of Subcutaneous Insulin Infusion

R. Bilous, J. Pickup, H. Keen, 1981, Diabetes.

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

J. Izzo, S. Ito, E. Ritz, 2009, Diabetologia.

Sodium‐Lithium Countertransport and Cardiorenal Abnormalities in Essential Hypertension

A. Semplicini, R. Trevisan, G. Viberti, 1991, Hypertension.

Cigarette smoking and diabetic nephropathy.

G. Viberti, M. Krimholtz, S. Thomas, 2000, Contributions to nephrology.

Single-blind studies of the effects of improved periodontal health on metabolic control in type 1 diabetes mellitus.

G. Viberti, R. Wilson, T. Watts, 1995, Journal of clinical periodontology.

Increased capillary permeability in diabetes mellitus and its relationship to microvascular angiopathy.

G. Viberti, 1983, The American journal of medicine.

Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria.

P. Groop, J. Ritter, J. Cockcroft, 1993, Clinical science.

Vascular responsiveness and cation exchange in insulin-dependent diabetes.

J. Ritter, A. Halkin, G. Viberti, 1991, Clinical science.

Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

G. Viberti, J. Karalliedde, 2007, Diabetes.

The effect of dietary changes on distinct components of the metabolic syndrome in a young Sri Lankan population at high risk of CVD

M. Gulliford, L. Gnudi, G. Viberti, 2016, British Journal of Nutrition.

Diabetic cardiorenal syndrome: insights into its pathogenesis

K. Earle, G. Viberti, J. Yip, 1992, Acta Diabetologica.

Enhanced growth and Na+/H+ antiport activity response to serum in cultured fibroblasts of diabetic patients with nephropathy

R. Trevisan, G. Viberti, G. Viberti, 1992, Acta Diabetologica.

Predisposition to essential hypertension and the development of diabetic nephropathy.

K. Earle, G. Viberti, 1992, Journal of the American Society of Nephrology : JASN.

The role of PC-1 and ACE genes in diabetic nephropathy in type 1 diabetic patients: evidence for a polygenic control of kidney disease progression.

M. Margaglione, A. Pizzuti, S. De Cosmo, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.

S. Bloom, H. Keen, G. Viberti, 1980, Metabolism: clinical and experimental.

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

H. Parving, G. Remuzzi, V. Perkovic, 2014, Journal of the American Society of Nephrology : JASN.

Cardiovascular risk in diabetic kidney disease: a model of chronic renal disease.

G. Viberti, S. Thomas, 2005, Kidney international. Supplement.

Sodium-Hydrogen Antiport, Cell Function and Susceptibility to Diabetic Nephropathy

R. Trevisan, G. Viberti, 1996 .

Prevalence of hypertension in Type 1 (insulin-dependent) diabetes mellitus

G. Viberti, 2004, Diabetologia.

Mechanical forces and TGF β 1 reduce podocyte adhesion through α 3 β 1 integrin downregulation

L. Gnudi, M. Baradez, G. Viberti, 2009 .

Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation.

L. Gnudi, M. Baradez, G. Viberti, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Early functional and morphological changes in diabetic nephropathy.

G. Viberti, 1979, Clinical nephrology.

Plasma Cholesteryl Ester Transfer Protein and Its Relationship to Plasma Lipoproteins and Apolipoprotein A-I-Containing Lipoproteins in IDDM Patients With Microalbuminuria and Clinical Nephropathy

M. Taskinen, P. Groop, G. Viberti, 1994, Diabetes Care.

Metabolic effects of physical exercise in insulin-dependent diabetics controlled by continuous subcutaneous insulin infusion or conventional injection therapy.

K. Alberti, R. Bilous, P. Home, 1984, Acta endocrinologica.

Lipolytic effect of intra-arterial injection of glucagon in man.

G. Pozza, G. Viberti, A. Ghidoni, 1971, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Blood Rheology and Cardiovascular Risk Factors in Type 1 Diabetes: Relationship with Microalbuminuria

D. Betteridge, G. Viberti, G. Viberti, 1991, Diabetic medicine : a journal of the British Diabetic Association.

The link between mechanical stretch and glucose metabolism--a conceptual advance in understanding diabetic (and non diabetic?) renal disease.

L. Gnudi, G. Viberti, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Biosynthetic Human Insulin: Progress and Prospects

J. Skyler, S. Raptis, E. Pfeiffer, 1981, Diabetes Care.

Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria

G. Viberti, A. Morocutti, M. Mattock, 1993, The Lancet.

Glomerular filtration rate gfr extracellular fluid volume ecv and atrial natriuretic factor anf in insulin dependent diabetics

N. Perico, G. Remuzzi, A. Benigni, 1988 .

Effect of ageing on insulin and growth hormone response to glucose and arginine in normal subjects

A. Pontiroli, G. Pozza, G. Viberti, 1974, Acta diabetologia latina.

Inhibitory effect of clofibrate on arginine-induced insulin secretion in chemical diabetes

A. Pontiroli, G. Pozza, G. Viberti, 1976, Acta diabetologia latina.

Effect of metergoline, a powerful and long-acting antiserotoninergic agent, on insulin secretion in normal subjects and in patients with chemical diabetes

A. Pontiroli, G. Pozza, G. Viberti, 1975, Diabetologia.

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow‐Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation

L. Ruilope, E. Ritz, H. Haller, 2014, Journal of the American Heart Association.

Detection of Potentially Reversible Diabetic Albuminuria: A Three-drop Agglutination Test for Urinary Albumin at Low Concentration

D. Vergani, G. Viberti, G. Viberti, 1982, Diabetes.

Inducible Overexpression of sFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic Mice

R. Bilous, L. Gnudi, Z. Webster, 2008, Diabetes.

Podocyte-Specific Induced Overexpression of Angiopoietin-2 Causes Proteinuria and Apoptosis of Glomerular Endothelia

R. Bilous, A. Woolf, L. Gnudi, 2007 .

Multiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease

M. Taskinen, P. Groop, A. Ekstrand, 1996, Diabetes.

Recent advances in understanding mechanisms and natural history of diabetic renal disease.

G. Viberti, 1988, Diabetes care.

ROSIGLITAZONE: POTENTIAL BENEFICIAL IMPACT ON CARDIOVASCULAR DISEASE

G. Viberti, G. Viberti, 2003, International journal of clinical practice.

Patient reactions to long-term outpatient treatment with continuous subcutaneous insulin infusion.

R. Bilous, J. Pickup, H. Keen, 1981, British medical journal.

c ontinuous Subcutaneous Insulin Infusion in the Treatment of Diabetes Mellitus

K. Alberti, J. Pickup, H. Keen, 1980 .

MICROALBUMINURIA AND DIABETES

H. Keen, G. Viberti, 1983, The Lancet.

Interventions based on microalbuminuria screening and low-protein diet in the treatment of kidney disease of diabetes mellitus.

G. Viberti, 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Plasma Insulin and C-Peptide After Subcutaneous and Intravenous Administration of Human Insulin (recombinant DNA) and Purified Porcine Insulin in Healthy Men

R. Bilous, J. Pickup, H. Keen, 1982, Diabetes Care.

Biosynthetic Human Insulin: Effect in Healthy Men on Plasma Glucose and Non-Esterified Fatty Acids in Comparison with Highly Purified Pork Insulin

R. Bilous, J. Pickup, H. Keen, 1981, Diabetes Care.

—to: Ong KK, Petry CJ, Emmett PM et al.; ALSPAC study team (2004) Insulin sensitivity and secretion in normal children related to size at birth, postnatal growth, and plasma insulin-like growth factor-I levels. Diabetologia 47:1064–1070

L. Gilardini, C. Invitti, A. Sartorio, 2004, Diabetologia.

Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.

J. Ritter, S. De Cosmo, G. Viberti, 1993, The Journal of laboratory and clinical medicine.

Proteinuria and diabetic control in insulin-dependent diabetes mellitus.

R. Bilous, J. Pickup, H. Keen, 1981, Acta endocrinologica. Supplementum.

St Vincent Declaration, 1994: Guidelines for the Prevention of Diabetic Renal Failure

R. Bilous, G. Viberti, C. Mogensen, 1994 .

Genetic factors and susceptibility to diabetic nephropathy.

W. Knowler, L. Rand, M. Steffes, 1988, New England Journal of Medicine.

Should we screen for microalbuminuria in essential hypertension?

G. Viberti, S. Thomas, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A quantitative ultrastructural study of juxtaglomerular arterioles in IDDM patients with micro- and normoalbuminuria

R. Østerby, G. Nyberg, G. Viberti, 1995, Diabetologia.

Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone.

D. Sugden, L. Gnudi, R. Buckingham, 2005, Journal of the American Society of Nephrology : JASN.

Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Prevents Albuminuria but Not Glomerulosclerosis in Experimental Diabetes

R. Bilous, L. Gnudi, R. Buckingham, 2010, American Journal of Nephrology.

Urine collection from disposable nappies

H. Keen, G. Viberti, I. Blumenthal, 1991, The Lancet.

Regulation of the Epithelial Brush Border Na+/H+ Exchanger Isoform 3 Stably Expressed in Fibroblasts by Fibroblast Growth Factor and Phorbol Esters Is Not through Changes in Phosphorylation of the Exchanger*

R. Huganir, M. Donowitz, C. Tse, 1997, The Journal of Biological Chemistry.

Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER

L. Ruilope, P. D. de Leeuw, J. Widimský, 2003, Hypertension.

Valsartan Improves Arterial Stiffness in Type 2 Diabetes Independently of Blood Pressure Lowering

G. Viberti, J. Botha, J. Karalliedde, 2008, Hypertension.

Evidence for renoprotection by blockade of the renin–angiotensin–aldosterone system in hypertension and diabetes

G. Viberti, J. Karalliedde, G. Viberti, 2006, Journal of Human Hypertension.

Why do we have to invoke genetic susceptibility for diabetic nephropathy?

G. Viberti, 1999, Kidney international.

Natural history and pathogenesis of diabetic nephropathy.

G. Viberti, J. Walker, 1991, The Journal of diabetic complications.

Effect of the antihistaminic agents meclastine and dexchlorpheniramine on the response of human growth hormone to arginine infusion and insulin hypoglycemia.

A. Pontiroli, G. Pozza, G. Viberti, 1976, The Journal of clinical endocrinology and metabolism.

Microalbuminuria Predicts Mortality in Noninsulin‐dependent Diabetes

G. Viberti, R. Jarrett, T. Murrells, 1984, Diabetic medicine : a journal of the British Diabetic Association.

Risk of nephropathy in diabetes mellitus: problems of methodology and terminology

G. Viberti, R. Jarrett, 1985, Diabetologia.

Does "afternoon diabetes" predict diabetes?

G. Viberti, R. Jarrett, H. A. Sayegh, 1978, British medical journal.

Determinants of response to insulin therapy following failure of oral agents in type 2 diabetes.

G. Viberti, Andy Smith, J. Karalliedde, 2005, Diabetes care.

Safety of continuous subcutaneous insulin infusion: Metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion

K. Alberti, R. Bilous, J. Pickup, 1982, Diabetologia.

Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe Obesity

A. Liuzzi, A. Brunani, G. Viberti, 2008, Clinical cardiology.

O-6: Microalbuminuria reduction with valsartan

G. Viberti, N. Wheeldon, 2001 .

No Change in Glomerular Heparan Sulfate Structure in Early Human and Experimental Diabetic Nephropathy*

J. van den Born, G. Viberti, L. Kjellén, 2006, Journal of Biological Chemistry.

Risk factors for renal and cardiovascular disease in diabetic patients.

G. Viberti, J. Messent, 1991, The Cardiology.

TGF-beta 1 and mechanical stretch reduce murine podocyte adhesion to extracellular matrix substrate and modulate beta 1 integrin expression/maturation in vitro

L. Gnudi, M. Baradez, G. Viberti, 2005 .

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.

N. Perico, F. Gaspari, G. Viberti, 2011, International journal of cardiology.

Microalbuminuria and Cardiovascular Disease

G. Viberti, S. Thomas, 2000 .

Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?

K. Borch-Johnsen, G. Viberti, C. Mogensen, 1993, BMJ.

Prevention of diabetic renal disease with special reference to microalbuminuria

H. Parving, P. Bennett, G. Jerums, 1995, The Lancet.

Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group.

R. Rizza, R. Bilous, R. Bergenstal, 1988, JAMA.

Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.

L. Gnudi, G. Viberti, G. Maltese, 2013, Clinical journal of the American Society of Nephrology : CJASN.

Podocyte number in normotensive type 1 diabetic patients with albuminuria.

G. Remuzzi, R. Bilous, S. De Cosmo, 2002, Diabetes.

Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta- carbonyl)-urea-diphosphate (FCE 21336).

A. Pontiroli, G. Viberti, R. Mangili, 1987, British journal of clinical pharmacology.

Renal Response to Restricted Protein Intake in Diabetic Nephropathy

H. Keen, G. Viberti, J. Bending, 1988, Diabetes.

Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

R. Buckingham, G. Viberti, J. Karalliedde, 2006, Journal of the American Society of Nephrology : JASN.

Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors

L. Gilardini, C. Invitti, C. Maffeis, 2006, International Journal of Obesity.

Plasmapheresis with immunosuppressive therapy vs immunosuppressive therapy alone for rapidly progressive anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis

G. Viberti, 2004 .

Diabetes mellitus: a major challenge in transplantation.

G. Viberti, G. Viberti, 2001, Transplantation proceedings.

Systemic Inflammation Precedes Microalbuminuria in Diabetes

L. Ruilope, S. Ito, T. Rabelink, 2019, Kidney international reports.

Hypertension and microalbuminuria as predictors of diabetic nephropathy.

G. Viberti, S. Jones, 1989, Diabete & metabolisme.

Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

G. Viberti, N. Wheeldon, 2002, Circulation.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Avosentan for overt diabetic nephropathy.

L. Ruilope, K. Jamerson, G. Viberti, 2010, Journal of the American Society of Nephrology : JASN.

A pragmatic lifestyle modification programme reduces the incidence of predictors of cardio-metabolic disease and dysglycaemia in a young healthy urban South Asian population: a randomised controlled trial

N. Fountoulakis, M. Gulliford, L. Gnudi, 2017, BMC Medicine.

Glycaemia, arterial pressure and micro-albuminuria in Type 1 (insulin-dependent) diabetes mellitus

H. Keen, R. J. Jarrett, H. Keen, 1984, Diabetologia.

Bedside estimation of microalbuminuria.

H. Keen, G. Viberti, C. Close, 1985, Lancet.

Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.

V. Mohan, L. Gnudi, V. Viswanathan, 2013, Clinical journal of the American Society of Nephrology : CJASN.

Predictors of rosiglitazone induced fluid retention

G. Viberti, A. Hider, J. Karalliedde, 2005 .

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

Matthias Herz, Markolf Hanefeld, M. Hanefeld, 2014, BMC Nephrology.

Increased Arterial Stiffness is an Independent Predictor of Renal Function Decline in Patients With Type 2 Diabetes Mellitus Younger Than 60 Years

N. Fountoulakis, L. Gnudi, G. Viberti, 2017, Journal of the American Heart Association.

Comparison of blood pressure measurement methods in adult diabetics

G. Viberti, Giancarlo Viberti, Athanasios E Raptis, 1997, The Lancet.

Strategies for the prevention of diabetic kidney disease: early antihypertensive treatment or improved glycemic control?

G. Viberti, D. Barnes, G. Viberti, 1994, Journal of diabetes and its complications.

Other Cardiovascular Risk Factors

G. Viberti, Stephen G. Thomas, 2010 .

High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria

M. Margaglione, R. Giorgino, A. Liuzzi, 1997, Diabetologia.

Commentary: the birth of microalbuminuria: a milestone in the history of medicine.

G. Viberti, J. Karalliedde, 2014, International journal of epidemiology.

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

B. Zinman, R. Holman, Daniel Levy, 2002, Diabetes care.

Introduction: Symposium on the Progress in Diabetic Nephropathy

S. Mauer, G. Viberti, C. E. Mogensen, 1992 .

Progression of subclinical polyneuropathy in young patients with Type 1 (insulin-dependent) diabetes: associations with glycaemic control and microangiopathy (microvascular complications)

R. Prescott, D. Ewing, B. Clarke, 1986, Diabetologia.

Neovascularization at the vascular pole region in diabetic glomerulopathy.

R. Osterby, G. Nyberg, G. Viberti, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.

B. Brenner, W. Gerth, S. Shahinfar, 2002, Kidney international. Supplement.

Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes.

L. De Angelis, D. Goldsmith, G. Viberti, 2005, Journal of the American Society of Nephrology : JASN.

Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine.

A. Pontiroli, G. Pozza, G. Viberti, 1977, Acta endocrinologica.

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.

J. Piercy, B. Hendry, G. Viberti, 1997, QJM : monthly journal of the Association of Physicians.

Obesity and the metabolic syndrome in children and adolescents.

L. Gilardini, C. Invitti, G. Viberti, 2004, New England Journal of Medicine.

Period prevalence of abnormal glucose tolerance and cardiovascular risk factors among obese children attending an obesity centre in Italy.

L. Gilardini, C. Invitti, G. Viberti, 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

PREVENTION OF MICROALBUMINURIA IN TYPE 2 DIABETES (ROADMAP TRIAL): 6A.02

L. Ruilope, J. Izzo, S. Ito, 2010 .

Glomerular response to hyperglycemia in human diabetic nephropathy.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 1990, The American journal of physiology.

Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.

G. Chatellier, S. Hadjadj, M. Marre, 2000, Diabetes care.

Mechanism of hypertension-mediated end-organ damage in diabetes

G. Viberti, 2003 .

Hypertension and microalbuminuria: Risk factors for cardiovascular disease in diabetes

G. Viberti, J. Karalliedde, 2005, Current Hypertension Reports.

Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuria

H. Parving, G. Remuzzi, N. Hollenberg, 2010, Journal of hypertension.

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

B. Zinman, R. Holman, W. Herman, 2006, Diabetes.

IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism.

L. Gnudi, G. Gruden, G. Viberti, 2003, Kidney international.

Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes

R. Bilous, H. Keen, G. Viberti, 1983, British medical journal.

Renal functional reserve in subjects with diabetes mellitus.

G. Viberti, S. Jones, 1995, Seminars in nephrology.

Abstract 426: The Diovan Reduction Of Proteinutria (Drop) Study: Albuminuria Response to High-Doses Of Valsartan in Type 2 Diabetes Mellitus

H. Parving, G. Remuzzi, N. Hollenberg, 2006 .

The need for tighter control of cardiovascular risk factors in diabetic patients.

G. Viberti, 2003, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Intermittent clinical proteinuria and renal function in diabetes

H. Keen, G. Viberti, J. Bending, 1986, British medical journal.

Glucose-induced hyperkalaemia: A hazard for diabetics?

G. Viberti, 1978, Lancet.

Genetic association analyses of non-synonymous single nucleotide polymorphisms in diabetic nephropathy

P. Deloukas, P. Whittaker, J. Morrison, 2008, Diabetologia.

Dietary Protein and the Diabetic Kidney

G. Viberti, J. Bending, M. Wiseman, 1987, Diabetic medicine : a journal of the British Diabetic Association.

High Prevalence of Cardio-Metabolic Risk Factors in a Young Urban Sri-Lankan Population

M. Gulliford, L. Gnudi, G. Viberti, 2012, PloS one.

HDL in CKD: How Good Is the "Good Cholesterol?"

R. Toto, K. Jamerson, G. Viberti, 2014 .

DIABRISK - SL Prevention of cardio-metabolic disease with life style modification in young urban Sri Lankan's - study protocol for a randomized controlled trial

M. Gulliford, L. Gnudi, G. Viberti, 2011 .

Predicting diabetic nephropathy.

G. Viberti, R. Jarrett, M. Wiseman, 1984, The New England journal of medicine.

Avosentan for overt diabetic nephropathy.

L. Ruilope, K. Jamerson, G. Viberti, 2010, Journal of the American Society of Nephrology : JASN.

Antibodies to human albumin epitopes in Type 1 (insulin-dependent) diabetes mellitus

D. Vergani, G. Viberti, R. Mangili, 1988, Diabetologia.

Early closure of European Pimagedine trial. Steering Committee. Safety Committee.

R. Bilous, G. Slama, H. Keen, 1997, Lancet.

Clinical application of pre-programmed insulin infusion: continuous subcutaneous insulin therapy with a portable infusion system.

K. Alberti, J. Pickup, H. Keen, 1979, Hormone and metabolic research. Supplement series.

Microalbuminuria in diabetes: Data dispersion: Author's reply

J Yip, H Vora, G C Viberti, 1993 .

Protein intake and blood glucose as modulators of GFR in hyperfiltering diabetic patients.

G. Viberti, E. Bognetti, M. Wiseman, 1992, Kidney international.

Commentary: the birth of microalbuminuria: a milestone in the history of medicine.

G. Viberti, J. Karalliedde, 2014, International journal of epidemiology.

GLUCOSE-INDUCED HYPERKALÆMIA: A HAZARD FOR DIABETICS?

G. Viberti, 1978, The Lancet.